Skip Navigation LinksHome > January 1, 2014 - Volume 65 - Issue 1 > Performance of 3 Rapid Tests for Discrimination Between HIV-...
JAIDS Journal of Acquired Immune Deficiency Syndromes:
doi: 10.1097/QAI.0b013e3182a97b81
Brief Report: Clinical Science

Performance of 3 Rapid Tests for Discrimination Between HIV-1 and HIV-2 in Guinea-Bissau, West Africa

Hønge, Bo Langhoff MD*,†; Bjarnason Obinah, Magnús Pétur BSc*,†; Jespersen, Sanne MD*,†; Medina, Candida MD; da Silva Té, David MD; José da Silva, Zacarias MD, PhD†,§; Østergaard, Lars MD, PhD, DMSc*; Laursen, Alex Lund MD, PhD, DMSc*; Wejse, Christian MD, PhD*,†,‖; Erikstrup, Christian MD, PhD; for the Bissau HIV Cohort Study Group

Collapse Box

Abstract

Abstract: As HIV-2 is intrinsically resistant to nonnucleoside reverse transcriptase inhibitors, it is mandatory to discriminate between HIV types before initiating antiretroviral treatment. Guinea-Bissau has the world's highest prevalence of HIV-2 and HIV-1/HIV-2 dually infected individuals. We evaluated 3 rapid tests for discrimination between HIV-1, HIV-2, and dual infections among 219 patients from Guinea-Bissau by comparing with the gold standard (INNO-LIA). Genie III HIV-1/HIV-2 was the best performer with regard to discriminatory capacity (agreement 91.8%), followed by Immunoflow HIV1-HIV2 (agreement 90.9%) and SD Bioline HIV-1/2 3.0 (agreement 84.5%). Our results underscore the need for evaluation of tests in relevant populations before implementation.

© 2014 by Lippincott Williams & Wilkins

Login

Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.